Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,459 people get ASTM articles and Market Currents by email alert.
Get email alerts on ASTM »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 3, 2013)
-
-
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 19, 2013)
-
-
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Apr 4, 2013)
-
-
-
GlobeNewswire (Mar 18, 2013)
-
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 6, 2013)
-
-
-
-
-
-
-
-
-
-
Aastrom Biosciences Q3/11 Earnings ResultsHenry McCusker • Wed, Nov 9, 2011
-
-
Aastrom Biosciences' Trial Meets Safety and Efficacy EndpointsM. E. Garza • Thu, Jun 2, 2011
-
-
-
-
-
-
-
-
-
Talking With Aastrom Biosciences Execs: Previewing Clinical Trial InfoM. E. Garza • Mon, Nov 15, 2010
-
Aastrom Biosciences, Inc. Q2 2008 Earnings Call TranscriptFri, Feb 8, 2008
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 3, 2013)
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 19, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Apr 4, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 6, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
GlobeNewswire (Dec 12, 2012)
-
GlobeNewswire (Dec 10, 2012)
-
GlobeNewswire (Nov 26, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 29, 2012)
-
GlobeNewswire (Oct 4, 2012)
-
GlobeNewswire (Sep 19, 2012)
ASTM vs. ETF Alternatives
Company Description
We are a regenerative medicine company (a medical area that focuses on developing therapies that regenerate damaged or diseased tissues or organs) that incorporated in 1989 and focuses on the clinical development of autologous cell products (cells collected from a patient and returned to that... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 11:15 AM Aastrom Biosciences (ASTM -4.1%) slips today despite posting a Q1 net loss of -$0.15, which was narrower than the prior year and beat analysts estimates for a loss of $0.19 per share. The company also reported cash guidance, saying that it had a total of $9.2M in cash and cash equivalents, compared to $13.6 million in cash and cash equivalents in December. The cash used for operations during Q1 came to $6.8M. Comment! [Healthcare, On the Move, Earnings]
- Wednesday, May 8, 6:50 PM Aastrom (ASTM): Q1 EPS of -$0.15 beats by $0.04. Revenue of $8K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 4, 3:43 PM Aastrom Biosciences (ASTM -1.9%) says the first patients have been enrolled in its ixCELL-DCM clinical trial, a study to assess the efficacy and safety of ixmyelocel-T in treating patients with advanced heart failure due to ischaemic dilated cardiomyopathy. The planned enrollment is for 108 patients at approximately 30 sites across the US. Comment! [Healthcare]
- Thursday, March 28, 3:19 PM The carnage in Aastrom Biosciences (ASTM -0.2%) appears to have abated, at least for now, as the stock drifts sideways after being down about 1.4% in pre-market trading. The drug developer sank nearly 38% yesterday to a new 52-week low after saying it was cutting about half of its workforce and making a strategic change in R&D programs, including halting late-stage trials of ixmyelocel-T for treating critical limb ischemia, instead turning its focus to treating dilated cardiomyopathy. Comment! [Healthcare]
-
Wednesday, March 27, 12:54 PM
Midday top 10 gainers: CHCI +45%. RVLT +35%. UEPS +24%. LIVE +20%. UTSI +20%. ECYT +11%. MFRM +10%. STSI +10%. PGTI +10%. GSL +10%.
Midday top 10 losers: ASTM -38%. EVBS -23%. ISNS -19%. ATOS -14%. CLF -15%. BAA -13%. GV -12%. LOGM -11%. MBLX -11%. LEDS -10%. Comment! [On the Move] - Wednesday, March 27, 9:32 AM Aastrom Biosciences (ASTM) craters 32% out the gate after saying it plans to cut its staff and operating costs by 50%, and end Phase III trials of its ixmyelocel-T drug for patients with critical limb ischemia - when there is an sudden lack of blood flow to a limb - as it was unable to bring in a partner. Instead, Aastrom will focus on Phase 2b trials of ixCELL for treating dilated cardiomyopathy (heart muscle disease). (PR) 2 Comments [Healthcare, On the Move]
-
Wednesday, March 27, 9:25 AM
Premarket gainers: CHCI +51%. UTSI +23%. STSI +14%. VELT +12%. CHTP +11%.
Losers: ASTM -37%. CLF -14%. GV -7%. LNDC -6%. Comment! [On the Move] - Tuesday, March 19, 2:52 PM Aastrom Biosciences (ASTM -7.8%) trades near its 52-week low today, after the company reported bigger Q4 losses Y/Y in yesterday's after hours session. Bottom line margins were hit hard by heavy SG&A charges for non-cash stock based compenstation, plus higher overall R&D costs. 1 Comment [Healthcare, On the Move, Earnings]
- Monday, March 18, 5:20 PM More on Aastrom Biosciences (ASTM): Q4 beats but losses more than double Y/Y, primarily due to charges and an increases in R&D expenses. Comment! [Healthcare, Earnings]
- Monday, March 18, 4:13 PM Aastrom (ASTM): Q4 EPS of -$0.18 beats by $0.05. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, October 4, 2012, 4:14 PM Aastrom Biosciences (ASTM) says that president and CEO Tim Mayleben has decided to retire once the company has hired a successor. Mayleben will continue to serve as a member of the board of directors after the transition. The company notes that it's initiated a search for a new chief executive. Shares -0.6% AH. Comment! [Healthcare]
-
Wednesday, August 8, 2012, 9:10 AM
Premarket gainers: WFR +31%. DF +28%. RAX +14%. LAMR +13%. CBB +12%. SODA +8%. CLWR +7%. KTOS +7%. ESRX +6%. HPQ +6%.
Losers: EZCH -21%. GIVN -16%. PCLN -15%. ATRS -9%. ASTM -9%. WCRX -8%. RL -7%. EXAS -5%. RENN -5%. Comment! [On the Move] - Friday, March 9, 2012, 11:38 AM Shares of Aastrom Biosciences (ASTM) come off a trading halt up 20.5% after the company says it landed a $40M private placement for its Series B convertible stock that helps it raise capital without diluting common stock shareholders for 5 years. Comment! [On the Move, Healthcare]
- Monday, September 19, 2011, 1:06 PM Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data from clinical trials for its drug ixmyelocel-T showed that treatment was well-tolerated, and efficacy observations were consistent with improved heart function. Comment! [Healthcare, On the Move]
- Friday, April 29, 2011, 11:53 AM A 2-1 ruling by a federal appeals court overturns a ban on federal stem-cell funding. STEM +8.1%, ASTM +2.6%, GERN +1%, CYTX +0.4%; PowerShares biotech and genome ETF (PBE) +0.3%. 6 Comments [Healthcare, On the Move]
-
Tuesday, January 18, 2011, 9:00 AM
Premarket gainers: ARIA +33%. SBIB +19%. HEV +10%. CXDC +9%. VOD +5%. TGB +4%. ERJ +4%. ASTM +4%. SNN +4%.
Losers: CMA -6%. AAPL -5%. AVGO -5%. C -5%. WLOCD -4%. GSK -4%. Comment!
-
- View all 0 replies
-
- View all 1 replies
-
FortSumter: I saw somewhere you mentioned $TTS. Do you have a current opinion? I like the analogy to $LL. Not much out there for dd.
-
- View all 0 replies
-
Joshua Hayes
Big Wave Trading Portfolio Update And Top Current Holdings http://bit.ly/WIktXd $KBE $XHB $VRNM $ASTM $CSU $CAMP $NTE - View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Neptune Technologies and Bioresources (NEPT), Aastrom Biosciences (ASTM), and Celsion (CLSN) look good. http://bit.ly/pJesA4 - View all 0 replies
-
- View all 0 replies
-
AAstromMan
Monday WIll ASTM be mentioned? Feb 07, 2011 Monday 9 PM National geographic http://on.natgeo.com/ihm9db - View all 0 replies
-
AAstromMan
http://bit.ly/hmznPA Billy amer story .. AM RADIO, DR. AMIT PATEL AND STEM CELLS ( ASTM ) saved my life - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
FortSumter: I saw somewhere you mentioned $TTS. Do you have a current opinion? I like the analogy to $LL. Not much out there for dd.